Metastatic NSCLCs With Limited Tissues: How to Effectively Identify Driver Alterations to Guide Targeted Therapy in Chinese Patients [0.03%]
有限组织样本的转移性NSCLC：如何有效识别驱动基因改变以指导中国患者的靶向治疗
Weihua Li,Yan Li,Lei Guo et al.
Weihua Li et al.
Introduction: Molecular diagnostics of newly diagnosed patients with metastatic NSCLC (mNSCLC) with limited tissue samples often face several obstacles in routine practice using next-generation sequencing (NGS), mainly ow...
Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504) [0.03%]
Glembatumumab Vedotin在晚期或转移性肺癌患者中的疗效和安全性(PrECOG 0504)研究
Saad A Khan,Zhuoxin Sun,Suzanne Dahlberg et al.
Saad A Khan et al.
Introduction: Glycoprotein NMB is a transmembrane protein linked with poor prognosis and is expressed in most squamous lung cancer. Glembatumumab vedotin is an antibody-drug conjugate targeting glycoprotein NMB, administe...
Epidemiology and Survival Outcomes for Patients With NSCLC in Scandinavia in the Preimmunotherapy Era: A SCAN-LEAF Retrospective Analysis From the I-O Optimise Initiative [0.03%]
免疫治疗前时代斯堪的纳维亚非小细胞肺癌患者的流行病学和生存结果：I-O优化计划中的SCAN-LEAF回顾性分析
Simon Ekman,Pia Horvat,Mats Rosenlund et al.
Simon Ekman et al.
Introduction: SCAN-LEAF, part of the I-O Optimise initiative, is a retrospective, longitudinal study investigating the epidemiology, clinical care, and outcomes for patients with NSCLC in Scandinavia. We report overall su...
Progressive Pleural Effusion as an Immune-Related Adverse Event in NSCLC: A Case Report [0.03%]
肺癌免疫治疗引起进行性胸腔积液一例报告
Chia-I Shen,Yi-Chen Yeh,Chao-Hua Chiu
Chia-I Shen
Immune checkpoint inhibitors (ICIs) have improved the clinical outcome of NSCLC. However, immune-related adverse events (irAEs) such as pneumonitis, thyroiditis, and colitis have been reported with the increasing use of ICIs. The diagnosis ...
Salvage Immunotherapy With Pembrolizumab in Patients Hospitalized for Life-Threatening Complications of NSCLC [0.03%]
帕博利珠单抗对因具有生命危险并发症的非小细胞肺癌住院患者的补救性免疫治疗研究
Ferréol Roborel de Climens,Christos Chouaid,Claire Poulet et al.
Ferréol Roborel de Climens et al.
Introduction: It is not known whether patients with NSCLC who are hospitalized because of cancer-related complications are liable to benefit from salvage immunotherapy. ...
Genomic and Transcriptomic Characterization of Relapsed SCLC Through Rapid Research Autopsy [0.03%]
快速研究式尸体检验对复发小细胞肺癌的基因组和转录组特征分析
Hui-Zi Chen,Russell Bonneville,Anoosha Paruchuri et al.
Hui-Zi Chen et al.
Introduction: Relapsed SCLC is characterized by therapeutic resistance and high mortality rate. Despite decades of research, mechanisms responsible for therapeutic resistance have remained elusive owing to limited tissues...
Trends in Molecular Testing of Lung Cancer in Mainland People's Republic of China Over the Decade 2010 to 2019 [0.03%]
2010至2019年中国大陆肺癌分子检测十年趋势研究
Wenbin Li,Yunfeng Lyu,Shaoming Wang et al.
Wenbin Li et al.
Introduction: Lung cancer is the leading cause of cancer-related morbidity and mortality in the People's Republic of China. Targeted therapies for patients with lung cancer, which depend on accurate identification of acti...
Intracranial Activity of Osimertinib Plus Capmatinib in a Patient With EGFR and MET-Driven Lung Cancer: Case Report [0.03%]
奥希替尼联合卡马替尼在EGFR和MET驱动的肺癌患者中的颅内活性：病例报告
Oliver Gautschi,Joachim Diebold
Oliver Gautschi
We previously published in the Journal of Thoracic Oncology the case of a patient with EGFR and MET-driven lung cancer and extracranial response to capmatinib and osimertinib. Here, we report on a second patient treated with the same combin...
Impact of a Lymph Node Specimen Collection Kit on the Distribution and Survival Implications of the Proposed Revised Lung Cancer Residual Disease Classification: A Propensity-Matched Analysis [0.03%]
淋巴结标本采集盒对建议修订的肺癌残余疾病分类分布及生存影响的作用：倾向匹配分析
Matthew P Smeltzer,Nicholas R Faris,Carrie Fehnel et al.
Matthew P Smeltzer et al.
Importance: The International Association for the Study of Lung Cancer (IASLC) has proposed a revision of the residual disease (R-factor) classification, to R0, 'R-uncertain', R1 and R2. We previously demonstrated longer ...
Retrospective Real-World Outcomes for Patients With ALK-Rearranged Lung Cancer Receiving ALK Receptor Tyrosine Kinase Inhibitors [0.03%]
接受ALK受体酪氨酸激酶抑制剂治疗的重排肺癌患者的实际世界结果的回顾性研究
Amanda J W Gibson,Adrian Box,Michelle L Dean et al.
Amanda J W Gibson et al.
Introduction: This study explored the use, safety, and efficacy of initial use of an ALK-inhibiting targeted therapy (ALK tyrosine kinase inhibitor [TKI]) in patients with ALK-rearranged NSCLC in a population-based, real-...